SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Short Candidates
An SI Board Since December 2000
Posts SubjectMarks Bans
897 95 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
447OK, folks, no, it doesn't have to the bottom of the barrel, just overvalued.tuck-3/20/2003
446Weird, this came on briefing about half hour ago, I see nothing in the news or otom pope-3/13/2003
445just that I was glad to see it, I'm short a few from yesterday at the close.tom pope-3/7/2003
444Anybody have comments on this from Briefing? >>9:33AM Imclone: May be timtuck-3/7/2003
443<< Does this profile fit "bottom of the barrel" to you? If so, pSpekulatius-3/6/2003
442Meant to state in prior post: Annual 5HT-3 CINV sales in 2002 were ~$900 millionWard Knutson-3/6/2003
441Annual CINV sales in 2002 were ~$900 million. Merck's drug is inferior in aWard Knutson-3/6/2003
440Spekulatius, Palo appears to be a better drug than the existing approved 5HT-3 Biomaven-3/6/2003
439My last post is a joke (in case somebody hasn't noticed <g>). The storSpekulatius-3/6/2003
438<< As we know, (1) i.p., preclinical work and early clinical studies have Spekulatius-3/5/2003
437<<don't know squat about the relative benefits of MOGN's palonosetSpekulatius-3/5/2003
436>>WASHINGTON (Dow Jones)--MedImmune Inc. said it was one of 26 pharmaceutituck-3/5/2003
435<i>As in even expanding the market that palo might address?</i> NotBiomaven-3/5/2003
434As in even expanding the market that palo might address? I wasn't assuming scaram(o)uche-3/5/2003
433>> I'll sniff around more and see if i'll find a better short opposcaram(o)uche-3/5/2003
432MRK's Emend is seeking a label for use in conjunction with a 5HT-3 blocker (Biomaven-3/5/2003
431don't know squat about the relative benefits of MOGN's palonosetron, butscaram(o)uche-3/5/2003
430MEDI short - to Tuck and the thread: thanks for all the input regarding MEDI. ItSpekulatius-3/5/2003
429I would short AMGN right here and right now. What a great setup. TSTheStockStalker-3/3/2003
428Direct to Consumer. Short Ideas? The first time I go after this strategy will keokalani'nui-2/28/2003
427direct to needle-shy consumer. (eom)scaram(o)uche-2/28/2003
426What does DTC stand for? FluMist looks good. Reimbursement has doubled (to $8)tuck-2/28/2003
425Just for conversation... Medi is a good--nay, a great--short if you think FluMikeokalani'nui-2/28/2003
424Cowen has just come out with a report saying that MEDI fundamentals are some ofBiomaven-2/28/2003
423Tuck, I agree that AMGN's valuation is comparable to MEDI's but this doeSpekulatius-2/28/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News